Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Dividend History

Company News

• Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

  Shuttle Pharmaceuticals Holdings, Inc. (SHPH) announced the closing of a $5.75 million underwritten public offering. The company plans to use the proceeds to fund its Phase II clinical trial, marketing, and general corporate purposes.

  Benzinga
• Shuttle Pharma Provides Third Quarter 2024 Corporate Update

  Shuttle Pharmaceuticals has successfully dosed the first three patients in its Phase 2 clinical trial of Ropidoxuridine for the treatment of glioblastoma, a deadly brain cancer. The company has also finalized agreements with six clinical trial sites and raised additional funding to support the trial.

  GlobeNewswire Inc.
• Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

  Shuttle Pharmaceuticals Holdings, Inc. announced the pricing of a $4.5 million public offering, with the proceeds to be used for clinical trials and general corporate purposes.

  Benzinga
• Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

  Shuttle Pharmaceuticals Holdings, Inc. announced the pricing of a $4.5 million public offering, with the proceeds to be used for clinical trials and general corporate purposes.

  GlobeNewswire Inc.
• Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

  Shuttle Pharmaceuticals announced the expansion of its Phase 2 clinical trial for Ropidoxuridine, a radiation sensitizer for treating glioblastoma, with four additional trial sites now prepared to enroll patients.

  GlobeNewswire Inc.